Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;30(1):1-14.
doi: 10.1038/eye.2015.203. Epub 2015 Oct 23.

Complement pathway biomarkers and age-related macular degeneration

M Gemenetzi  1 , A J Lotery  2   3
Affiliations
Review

Complement pathway biomarkers and age-related macular degeneration

M Gemenetzi et al. Eye (Lond). 2016 Jan.

Abstract

In the age-related macular degeneration (AMD) 'inflammation model', local inflammation plus complement activation contributes to the pathogenesis and progression of the disease. Multiple genetic associations have now been established correlating the risk of development or progression of AMD. Stratifying patients by their AMD genetic profile may facilitate future AMD therapeutic trials resulting in meaningful clinical trial end points with smaller sample sizes and study duration.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. 1'Highlights of Prescribing Information (Macugen)'. Food and Drug Administration: 3–12. July 2007.
    1. 2Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431. - PubMed
    1. 3Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26(5): 495–511. - PubMed
    1. 4Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration:etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48(3): 257–293. - PubMed
    1. 5van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol 2003; 18(9): 845–854. - PubMed

MeSH terms